Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
CHINA OILFIELD
02883
5
CNOOC
00883
CN Stock MarketDetailed Quotes
Hubei Biocause Heilen Pharmaceutical (301211)
- 11.40
- -0.04-0.35%
Market Closed Apr 24 15:00 CST
4.76BMarket Cap140.74P/E (TTM)
11.48High11.25Low34.79KlotVolume11.40Open11.44Prev Close39.56MTurnover0.83%Turnover Ratio135.71P/E (Static)417.60MShares16.9552wk High2.09P/B4.76BFloat Cap10.5952wk Low13.73Limit Up417.60MShs Float31.59Historical High9.15Limit Down2.01%Range %8.43Historical Low0.17Dividend TTM11.37Avg Price14.12KlotAsk1.51%Div Yield TTM100Lot Size19.61KlotBid
Hubei Biocause Heilen Pharmaceutical (301211) Income Statement
All
YOY
| (Q1)Mar 31, 2026 | (FY)Dec 31, 2025 | (Q9)Sep 30, 2025 | (Q6)Jun 30, 2025 | (Q1)Mar 31, 2025 | (FY)Dec 31, 2024 | (Q9)Sep 30, 2024 | (Q6)Jun 30, 2024 | (Q1)Mar 31, 2024 | (FY)Dec 31, 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total operating revenue | 5.00%120.16M | 1.67%453.31M | -4.52%318.9M | -2.93%234.77M | -17.10%114.45M | -32.75%445.86M | -38.43%333.99M | -40.39%241.87M | -28.57%138.06M | 28.76%663.03M |
| Operating revenue | 5.00%120.16M | 1.67%453.31M | -4.52%318.9M | -2.93%234.77M | -17.10%114.45M | -32.75%445.86M | -38.43%333.99M | -40.39%241.87M | -28.57%138.06M | 28.76%663.03M |
| Other operating revenue | ---- | -7.44%7.5M | ---- | -87.48%429.94K | ---- | -30.15%8.11M | ---- | 56.98%3.43M | ---- | 256.20%11.61M |
| Total operating cost | 7.35%119.11M | 19.86%439.87M | 20.76%318.61M | 38.92%228.43M | 16.83%110.96M | -21.54%367M | -29.52%263.84M | -39.85%164.43M | -34.36%94.97M | 24.31%467.72M |
| Operating cost | 6.68%95.02M | 11.29%353.1M | 8.75%253.41M | 18.45%183.35M | 3.91%89.07M | -20.02%317.27M | -27.50%233.02M | -37.05%154.79M | -34.58%85.71M | 8.32%396.67M |
| Operating tax surcharges | 27.15%1.51M | 40.15%5.95M | 35.22%3.87M | 29.28%2.85M | 106.38%1.19M | -28.19%4.25M | -35.90%2.86M | -29.28%2.2M | -68.57%575.61K | 49.40%5.92M |
| Operating expense | -17.31%5.1M | -10.01%20.64M | -1.06%16.39M | 13.20%11.77M | 4.96%6.17M | -4.78%22.93M | -5.17%16.57M | -22.22%10.4M | -10.68%5.88M | 61.58%24.08M |
| Administration expense | 10.10%11.49M | 14.22%44.88M | 12.50%32.88M | 10.34%21.22M | 8.67%10.44M | 1.04%39.29M | -17.30%29.23M | 1.11%19.23M | -1.57%9.6M | 6.35%38.89M |
| Financial expense | 119.87%493.55K | 80.11%-9.88M | 81.53%-8.15M | 85.51%-6.01M | 86.00%-2.48M | 1.83%-49.69M | -12.23%-44.11M | -47.06%-41.49M | -52.82%-17.74M | 22.40%-50.62M |
| -Interest expense (Financial expense) | -41.34%27.99K | -42.66%179.05K | -26.69%134.2K | -21.15%98.6K | -24.56%47.72K | 1.57%312.27K | -10.12%183.05K | -6.24%125.05K | 6.01%63.25K | -10.74%307.43K |
| -Interest Income (Financial expense) | 51.45%-1.28M | 74.52%-11.94M | 78.91%-9.13M | 84.36%-6.19M | 84.60%-2.63M | 2.01%-46.88M | -19.30%-43.3M | -60.99%-39.58M | -39.13%-17.11M | 21.60%-47.84M |
| Research and development | -16.44%5.5M | -23.55%25.18M | -23.10%20.2M | -20.95%15.25M | -39.87%6.58M | -37.59%32.94M | -24.80%26.27M | -4.55%19.3M | 53.73%10.94M | 165.94%52.77M |
| Credit Impairment Loss | -106.70%-372.33K | -214.15%-234.05K | 160.28%402.03K | -19.26%-732.88K | 44.83%-180.13K | -112.49%-74.5K | -1,929.16%-666.97K | 18.64%-614.54K | -177.21%-326.5K | -65.28%596.61K |
| Asset Impairment Loss | ---- | ---4.35M | ---2.03M | ---2.03M | ---- | ---- | ---- | ---- | ---- | ---- |
| Other net revenue | 1.90%9.2M | 29.10%28.42M | 82.87%23.42M | 281.51%14.1M | 619.16%9.03M | 119.48%22.01M | 319.93%12.81M | 159.87%3.7M | 359.12%1.26M | -0.51%10.03M |
| Fair value change income | 4.67%7.41M | -11.04%12.97M | 70.28%17.17M | 298.84%10.57M | 646.34%7.07M | 262.67%14.58M | --10.08M | --2.65M | --947.92K | --4.02M |
| Invest income | ---- | 263.36%16.17M | 300.27%4.72M | 339.22%4.28M | 1,389.94%513.1K | --4.45M | --1.18M | --975.1K | --34.44K | ---- |
| Asset deal income | ---- | --11.87K | --11.87K | --11.87K | ---- | ---- | ---- | ---- | ---- | 327.18%177.18K |
| Other revenue | 33.71%2.17M | 25.91%3.85M | 42.42%3.15M | 191.56%2M | 170.27%1.62M | -41.58%3.06M | -51.98%2.22M | -81.53%684.82K | -3.33%599.48K | -37.08%5.24M |
| Operating profit | -18.10%10.25M | -58.51%41.86M | -71.43%23.7M | -74.81%20.44M | -71.77%12.52M | -50.87%100.88M | -51.53%82.96M | -39.36%81.13M | -7.84%44.34M | 38.06%205.33M |
| Add:Non operating Income | ---- | 7,748.86%470.93K | 39.24%117.56K | 26.49%106.8K | -94.90%2.65K | -98.00%6K | -55.40%84.43K | 145.98%84.43K | 790.36%52.08K | --299.28K |
| Less:Non operating expense | -97.75%419.63 | 127.21%1.07M | 52.73%705.46K | -93.51%21.36K | -73.05%18.66K | -83.35%469K | -19.08%461.9K | 83.21%329.03K | -61.43%69.25K | 119.49%2.82M |
| Total profit | -18.00%10.25M | -58.91%41.26M | -72.01%23.12M | -74.63%20.52M | -71.80%12.5M | -50.49%100.42M | -51.65%82.58M | -39.48%80.89M | -7.54%44.32M | 37.56%202.82M |
| Less:Income tax cost | -52.54%1.03M | -28.42%6.35M | -72.43%2.18M | -84.06%1.97M | -68.68%2.17M | -66.77%8.87M | -69.86%7.92M | -39.88%12.39M | -13.39%6.94M | 23.33%26.7M |
| Net profit | -10.73%9.22M | -61.87%34.91M | -71.96%20.93M | -72.92%18.55M | -72.38%10.33M | -48.02%91.55M | -48.34%74.66M | -39.40%68.5M | -6.37%37.38M | 40.00%176.12M |
| Net profit from continuing operation | -10.73%9.22M | -61.87%34.91M | -71.96%20.93M | -72.92%18.55M | -72.38%10.33M | -48.02%91.55M | -48.34%74.66M | -39.40%68.5M | -6.37%37.38M | 40.00%176.12M |
| Net profit of parent company owners | -10.73%9.22M | -61.87%34.91M | -71.96%20.93M | -72.92%18.55M | -72.38%10.33M | -48.02%91.55M | -48.34%74.66M | -39.40%68.5M | -6.37%37.38M | 40.00%176.12M |
| Earning per share | ||||||||||
| Basic earning per share | 0.00%0.02 | -63.64%0.08 | -72.22%0.05 | -75.00%0.06 | -84.62%0.02 | -63.93%0.22 | -64.00%0.18 | -38.46%0.24 | -7.14%0.13 | 38.64%0.61 |
| Diluted earning per share | 0.00%0.02 | -63.64%0.08 | -72.22%0.05 | -75.00%0.06 | -84.62%0.02 | -63.93%0.22 | -64.00%0.18 | -38.46%0.24 | -7.14%0.13 | 38.64%0.61 |
| Other composite income | 307.10%628.95K | -49.3K | -303.69K | |||||||
| Other composite income of parent company owners | ---- | 307.10%628.95K | ---- | ---49.3K | ---- | ---303.69K | ---- | ---- | ---- | ---- |
| Total composite income | -10.73%9.22M | -61.05%35.54M | -71.96%20.93M | -72.99%18.5M | -72.38%10.33M | -48.19%91.24M | -48.34%74.66M | -39.40%68.5M | -6.37%37.38M | 40.00%176.12M |
| Total composite income of parent company owners | -10.73%9.22M | -61.05%35.54M | -71.96%20.93M | -72.99%18.5M | -72.38%10.33M | -48.19%91.24M | -48.34%74.66M | -39.40%68.5M | -6.37%37.38M | 40.00%176.12M |
| Currency Unit | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY |
| Accounting Standards | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) |
| Audit Opinions | -- | Unqualified opinion | -- | -- | -- | Unqualified opinion | -- | -- | -- | Unqualified opinion |
| Auditor | -- | Daxin Certified Public Accountants (Special General Partnership) | -- | -- | -- | Daxin Certified Public Accountants (Special General Partnership) | -- | -- | -- | Daxin Certified Public Accountants (Special General Partnership) |
FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.
Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.
Market Insights
Hot Topics Hot Topics
Middle East conflict spreads to the stock market! How should investors respond?
Signs of restarting the second round of US-Iran talks have emerged. According to reports, Iran's foreign minister arrived in Pakistan on Fri
牛牛課堂
Mar 4 17:09
Long-term answers | Your account on the left shrinks, while your right hand is chased by the times — Be the person that no bombardment can ever wipe out.
牛牛課堂
Mar 18 18:18
Hormuz, Term Structure and USO: Navigating the Energy Storm